HCA Healthcare, IncNYSE: HCA
Health Care · Health Care Facilities
$391.08
-0.38%
Vol: 100K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21HCA shares fall as workforce cuts and cost outlook weigh ahead of RBC conferenceNegative▶
HCA Healthcare stock declined approximately 3.5% on May 19 as investors digested reports of non-clinical layoffs, which the company confirmed as a 'small portion' of its workforce. The pressure came ahead of HCA's appearance at the RBC Capital Markets Global Healthcare Conference on May 20, where SVP and Controller Chris Wyatt presented. Investors continue to weigh the company's reaffirmed $600M-$900M EBITDA headwind from APTC subsidy expiration against its Q1 revenue growth of 4.3%.
May 20HCA shares fell roughly 3.5% on May 19 on renewed scrutiny of non-clinical layoffs and cost outlook ahead of its May 20 RBC Global Healthcare Conference presentation.Negative▶
HCA Healthcare slid about 3.5% on May 19 as investors weighed reports of non-clinical workforce reductions and cost pressures ahead of CEO presentations at the RBC Global Healthcare Conference scheduled for May 20 at 11:30am ET. HCA described the layoffs as a small portion of its workforce while emphasizing continued hiring elsewhere. The company recently completed a $3.0B public offering of senior unsecured notes due 2031, 2033 and 2036 to diversify long-term funding. Cynthia Cifuentes-Finkel was named SVP of marketing and corporate affairs effective June 8. AustralianSuper added more than 95,000 shares in mid-May. Analyst consensus is Moderate Buy with average price target around $517.82 versus current price near $403.66.
May 19HCA Healthcare proposed a senior notes offering through subsidiary HCA Inc. for general corporate purposes including potential debt repayment, and confirmed an RBC Global Healthcare Conference presentation on May 20.Neutral▶
HCA Healthcare's wholly owned subsidiary HCA Inc. announced a proposed offering of senior notes with terms to be set by market conditions, with proceeds earmarked for general corporate purposes including potential repayment of outstanding borrowings. The company also confirmed its presentation at the RBC Global Healthcare Conference on May 20, 2026, where investor focus will be on payer-mix and exchange-coverage trends. Separately, AustralianSuper acquired more than 95,000 HCA shares in mid-May, and HCA named Cynthia Cifuentes-Finkel SVP of marketing and corporate affairs effective June 8. Why it matters: a refinancing keeps HCA's capital structure flexible, and Wall Street still rates the stock a Moderate Buy with an average price target near $518 versus a ~$429 quote, implying ~21% upside on full-year 2026 EPS of roughly $30. The bear case: shares are still ~23% below their 52-week high after Q1 revenue merely matched consensus, a weaker flu season pressured volumes and investor unease about insurance-coverage changes (Medicaid/exchange exposure) remains the dominant overhang.
May 18HCA Healthcare stock rose 1.21% to $432.70 on May 14, 2026 (still 22.25% below 52-week high $556.52) as investors weighed a Q1 EPS miss ($7.15 vs $7.16) against the $600M-$900M EBITDA headwind from ACA policy changes, with consensus Moderate Buy and average PT ~$517.82.Mixed▶
HCA Healthcare shares closed at $432.70 on May 14, 2026, up 1.21% on the day but still 22.25% below the 52-week high of $556.52, reflecting investor anxiety after a slight Q1 2026 EPS miss of $7.15 versus $7.16 consensus (revenue grew 4.3%; adjusted EBITDA up ~2% YoY). The debate centers on whether HCA's scale can offset a direct $600M-$900M EBITDA headwind from forthcoming ACA policy changes. The company is enhancing funding strategy with a $3B public senior notes offering for general corporate purposes including refinancing existing borrowings. Management is presenting at the RBC Global Healthcare Conference on May 20. AustralianSuper added 95,000+ shares per a mid-May filing. Bear case: payer-mix deterioration from ACA changes could break HCA's compounding growth narrative; insider selling continues.
May 15HCA Healthcare named Cynthia Cifuentes-Finkel SVP of Marketing and Corporate Affairs effective June 8 and will present at RBC Global Healthcare Conference May 20.Neutral▶
HCA Healthcare named Cynthia Cifuentes-Finkel senior vice president of marketing and corporate affairs effective June 8, 2026, reporting to Mike McAlevey. The company is scheduled to present at the RBC Global Healthcare Conference on May 20. HCA Inc. proposed a senior notes offering with terms dependent on market conditions, signaling balance-sheet maneuvering. HCA Florida Gainesville Hospital is opening in May. The stock trades near $429, ~23% below its 52-week high amid investor concerns around ACA policy headwinds ($600-900M potential EBITDA impact) and weaker inpatient volumes after a softer flu season. Analyst consensus is Buy with a $513 price target.
May 14HCA Healthcare disclosed a senior notes offering and new SVP marketing appointment amid ACA policy headwind concernsMixed▶
HCA Healthcare announced on May 13 that Virginia Retirement Systems lowered its stake, while the company prepares for the RBC Global Healthcare Conference on May 20. HCA Inc. proposed a new senior notes offering with terms dependent on market conditions, following its $3 billion senior notes completion on April 30. The company named Cynthia Cifuentes-Finkel as senior VP of marketing and corporate affairs effective June 8. HCA Florida Gainesville Hospital opened May 5, a $235M investment creating 250+ jobs. The bear case centers on a direct $600M-$900M EBITDA headwind from ACA policy changes, with Q1 2026 EPS of $7.15 narrowly missing the $7.16 consensus and operating margin contracting to 12.0% from 12.7% YoY.
May 13HCA Healthcare shares remain under pressure following Q1 2026 results despite raised earnings while analysts maintain a Buy consensus with $511 price target.Mixed▶
HCA reported Q1 2026 revenue up 4.3% to $19.1B with diluted EPS up 10.9% to $7.15, but shares fell about 8% on the April release and remain down 9.1% over the last 30 days. The company completed a $3B senior notes offering on April 30 as part of refinancing efforts. California Attorney General also disclosed a $1.53M settlement (part of $2.9M total across CA/CO/NV) over nurse training repayment agreements. Stock trades around $429 with 20 analysts averaging a Buy rating and a $511.84 12-month target, implying ~18.5% upside. The mild respiratory season and insider selling are cited as caution flags, but earnings growth outlook remains intact.
May 12HCA Healthcare opens $235M Florida Gainesville Hospital and prepares May 20 RBC Healthcare Conference presentation as analysts maintain Buy with $511 average target.Mixed▶
On May 5, 2026 HCA Florida Gainesville Hospital opened to patients, the first full-service hospital in the region in 50+ years, backed by a $235M investment expected to add 250+ jobs. HCA also completed a $3B senior notes offering on April 30 to fund growth and refinancing. Shares trade near $435, down ~23% from a 52-week high of $557 after Q1 EPS growth of 11% was overshadowed by softer inpatient volumes from a weak flu season. Management is scheduled to present at the RBC Global Healthcare Conference on May 20. Cynthia Cifuentes-Finkel was named SVP of marketing and corporate affairs effective June 8. Risk: continued volume softness and congressional pricing scrutiny could pressure margins.
May 11No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 8HCA reports Q1 revenue of $19.1B (+4.3%) with 10.9% EPS growth to $7.15, offsetting recent 9% stock declinePositive▶
HCA Healthcare reported first-quarter 2026 results with revenues up 4.3% to $19.109 billion and diluted EPS up 10.9% to $7.15. Adjusted EBITDA grew 1.9% to $3.802 billion with operating cash flows up 22.0%. Same facility admissions grew 0.9%. Despite strong earnings beat, shares fell 8% in early April trading due to concerns over lower inpatient volumes tied to a weaker flu season. Analysts maintain consensus price target near $513, implying 19% upside from current levels.
May 6HCA Healthcare reports Q1 2026 revenue of $19.1B (+4.3% YoY) with diluted EPS up 10.9% to $7.15; stock recently rebounded from April sell-off.Positive▶
HCA Healthcare delivered Q1 2026 results showing 4.3% revenue growth to $19.1 billion and 10.9% diluted EPS growth to $7.15, with same-facility admissions up 0.9%. The stock fell 8% initially on April 24 due to temporary respiratory season headwinds and lower patient volumes, but has since rebounded as investors focus on reaffirmed 2026 guidance and upcoming investor presentations. Several analysts reiterated Buy ratings with Argus highlighting meaningful upside potential. Risk factors include temporary volume headwinds and insider selling concerns that temper the positive momentum.
May 5HCA Healthcare Q1 beats EPS 11% but stock falls 8% on modest EBITDA growthMixed▶
HCA Healthcare Q1 2026 revenues $19.109B (up 4.3% YoY) with net income $1.620B (up 0.6%). Diluted EPS $7.15 (up 10.9%) beating expectations, adjusted EBITDA $3.802B (up 1.9%), operating cash flow $2.014B (up 22%). Stock fell ~8% post-earnings despite EPS beat. 20 analysts average Buy with $511.84 target (18.5% upside). Lower respiratory volumes and winter storms impacted Q1. Expanding outpatient services now 38.3% of revenues. Targeting market share increase from 27% to 29% by 2030. Full-year guidance reaffirmed. Cost savings and network expansion support future growth. Insider selling and mixed sentiment temper upside.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| HCAHCA | $391.08 | -0.38% | -7.2% | 11.8x | 1.19 | $87.1B |
| UHSUNIVERSAL | $146.80 | -9.63% | -4.0% | 6.4x | 1.13 | $9.8B |
| LLYELI | $1,119.42 | +7.47% | +5.4% | 23.4x | 0.48 | $928.9B |
| JNJJOHNSON | $237.09 | +2.31% | +1.2% | 18.2x | 0.26 | $557.8B |
| ABBVABBVIE | $222.45 | +3.70% | +2.4% | 13.2x | 0.30 | $379.0B |
| UNHUNITEDHEALTH | $404.01 | +5.63% | -2.2% | 18.4x | 0.65 | $347.3B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.